Document:

<PAGE>

                                                                   Exhibit 10.12

                      INVENTORY TRADEMARK LICENSE AGREEMENT

     This Inventory Trademark License Agreement ("Agreement") is made and
entered into this 14th day of April, 2006, by and between Abbott Laboratories, a
corporation organized and existing under the laws of the State of Illinois and
having a principal place of business at 100 Abbott Park Road, Abbott Park,
Illinois 60064 ("Licensor") and ImaRx Therapeutics, Inc., a corporation
organized and existing under the laws of Delaware and having a principal place
of business at 1635 East 18th Street, Tucson, Arizona 85719 ("Licensee").

     WHEREAS, Licensor and Licensee (each a "Party" and, collectively, the
"Parties") have entered into an Asset Purchase Agreement dated April 10, 2006
(the "Asset Purchase Agreement"), pursuant to which Licensee has agreed to
acquire, and Licensor has agreed to sell, certain assets of the Licensor's
pharmaceutical products division;

     WHEREAS, the assets to be transferred include an Inventory of the Products
(as defined in the Asset Purchase Agreement); and

     WHEREAS, Licensee desires to obtain a trademark and trade name license to
promote, market and sell certain Products existing as of the Closing Date (as
defined in the Asset Purchase Agreement); and

     WHEREAS, Licensor is willing to grant such a license upon the terms and
conditions set forth below.

     NOW, THEREFORE, in consideration of entering into the Asset Purchase
Agreement and the mutual agreements and undertakings contained herein and for
other good and valuable consideration (the receipt and sufficiency of which is
hereby acknowledged), the Parties agree as follows.

1. DEFINITIONS:

     Capitalized terms used in this Agreement and not otherwise defined herein
shall have the meanings assigned to them in the Asset Purchase Agreement. For
purposes of this Agreement, the following words and phrases shall have the
following meanings:

     1.1 "Licensed Marks" shall mean: those trademarks identified on Schedule 1
attached hereto.

     1.2 "Losses" shall mean all damages, liabilities, costs and expenses,
including settlement and arbitration costs and reasonable attorneys' fees and
costs.

     1.3 "Territory" shall mean, for each Licensed Mark, each of those
territories in which Licensor or its Affiliates owns or possesses rights to such
Licensed Mark.

2. GRANT

                                       -1-

<PAGE>

     2.1 During the term of this Agreement, and subject to the terms and
conditions hereof and of the Asset Purchase Agreement, the Licensor hereby
grants to the Licensee, in the Territory, an exclusive, fully paid-up,
non-transferable and non-assignable license, without the right to sublicense
("Inventory Trademark License"), to use the Licensed Marks solely in connection
with the promotion, marketing and sale of the Inventory in the Territory.

     2.2 Notwithstanding anything else in this Agreement to the contrary, absent
Licensor's express prior written consent, Licensee's use of the Licensed Marks
shall cease at the end of the earlier of (i) the completion of the sale of all
Inventory by Licensee, and (ii) the date upon which the expiration date for all
Inventory has expired, at which time the Inventory Trademark License shall
automatically terminate without further action by either Party and Licensee
shall cease all use of the Licensed Marks, except for commercially reasonable
ancillary use to the extent required for regulatory purposes relating to the
Inventory for a period of up to 24 months after the termination of this
Agreement.

     2.4 Without the prior written consent of Licensor, Licensee shall have no
power or right to, and shall not, sell, assign, sublicense or otherwise transfer
the Inventory Trademark License to any Person, including by a change of control
of Licensee, or by operation of law, except for (i) sublicensing, with
Licensor's prior written consent, within Licensee's trade channels solely for
the purposes of selling and marketing the Inventory, and (ii) to any permitted
assignee of Licensee's rights and obligations under the Asset Purchase Agreement
to the extent permitted therein.

     2.5 Licensee shall comply with all applicable laws, rules, regulations,
ordinances, permits and licenses when exercising its rights under this
Agreement, including in the manufacture, promotion, marketing and sale of
Products.

3. PROTECTION OF THE LICENSED MARKS

     3.1 Licensee understands and agrees that (a) Licensee shall not directly or
indirectly challenge Licensor's sole and exclusive ownership of all right, title
and interest in and to the Licensed Marks, including the goodwill associated
therewith, and (b) all goodwill arising from the use of the Licensed Marks shall
inure solely to the benefit of Licensor. Furthermore, Licensee shall not assist
any third party in challenging Licensor's right, title and interest in and to
the Licensed Marks.

     3.2 Nothing contained in this Agreement shall be construed as an assignment
to the Licensee of any right, title or interest in the Licensed Marks, it being
understood that all rights, title and interests relating to the Licensed Marks
are expressly reserved by the Licensor except for the rights being expressly
licensed hereunder.

     3.3 No right or license as to any of Licensor's intellectual property or
products is being granted hereunder, except as expressly provided herein.

     3.4 Licensee shall not use the Licensed Marks other than as permitted
hereunder and, in particular, shall not incorporate Licensor's name or the
Licensed Marks in Licensee's

                                       -2-

<PAGE>

corporate or business name in any manner whatsoever. In using the Licensed
Marks, Licensee will in no way represent that it has any rights, title or
interest in the Licensed Marks other than those expressly granted under the
terms of this Agreement, and Licensee shall not represent itself as an
"authorized representative of," or indicate in any other way any affiliation
with, Licensor.

     3.5 Licensor shall, at its expense, use commercially reasonable efforts to
maintain in full force and effect all existing registrations of the Licensed
Marks until the termination of this Inventory Trademark License. Licensee shall,
at Licensor's expense, take all actions reasonably requested by Licensor to
assist Licensor in defending or prosecuting any action or suit relating to the
Licensed Marks as used in connection with this Agreement.

     3.6 Licensee shall notify Licensor promptly if Licensee learns of any
infringement or pending or threatened litigation involving the Licensed Marks as
used in connection with this Agreement.

     3.7 Licensee agrees not to adopt or use any trade name or trademark which
is confusingly similar or likely to cause confusion with the Licensed Marks.
Furthermore, Licensee agrees not to seek registration of any of the Licensed
Marks or any trade name or trademark confusingly similar thereto.

4 QUALITY CONTROL

     4.1 Licensee shall use the Licensed Marks only with respect to the
promotion, marketing and sale of the Inventory as provided herein, and shall not
affix any Licensed Marks to any products other than Products, or use any
Licensed Marks in connection with any service (other than as necessary to market
and sell Products).

     4.2 All Products promoted, marketed and sold by Licensee under the Licensed
Marks shall be of the same quality as the Products sold by Licensor under the
Licensed Marks immediately prior to the Closing Date, and Licensee shall
otherwise use the Licensed Marks in a manner consistent with Licensor's use,
immediately prior to the Closing Date, of the Licensed Marks in connection with
the Products. At Licensor's request, Licensee shall provide to Licensor
representative samples of Licensee's use of the Licensed Marks and permit
Licensor to inspect Licensee's facilities as necessary for Licensor to confirm
Licensee's compliance with this Article 4, provided that Licensor agrees to
provide a minimum of ten (10) days' prior written notice before conducting any
such inspection, and any such inspection shall be conducted during regular
business hours and in a manner that is not disruptive to Licensee's business
operations.

     4.3 In using the Licensed Marks as permitted hereunder in connection with
the promotion, marketing and sale of the Inventory, Licensee shall duly include
all notices and legends with respect to the Licensed Marks as may be required by
applicable federal, state or local trademark laws or which may be reasonably
requested by Licensor.

5. GOODWILL AND IRREPARABLE HARM

                                       -3-

<PAGE>

     5.1 Licensee acknowledges that its failure to manufacture, sell, promote,
and distribute the Products or otherwise use the Licensed Marks in accordance
with the provisions of this Agreement will result in immediate and irreparable
damage to Licensor and that Licensor may have no adequate remedy at law for such
failures by Licensee.

     5.2 Licensee further agrees that in the event of any breach of this
Agreement by Licensee, Licensor, in addition to all other remedies available to
it hereunder, shall be entitled to injunctive relief against any such breach as
well as such other relief as any court with jurisdiction may deem just and
proper.

6. REPRESENTATIONS AND WARRANTIES

     6.1 Licensor represents and warrants to Licensee that it has all rights,
power and authority necessary to grant the rights set out in this Agreement.

     6.2 Licensor represents and warrants that Licensee's exercise of its rights
under the Inventory Trademark License in accordance with the terms of this
Agreement will not, to Licensor's knowledge, infringe upon the trademark rights
of any third party. Licensor shall defend, indemnify and hold harmless Licensee
and its agents and employees from and against any and all Losses arising out of
any claim that, if true, would mean that Licensor has breached the above
representation and warranty.

     6.3 Licensee shall defend, indemnify and hold harmless Licensor and its
agents and employees from and against any and all Losses arising out of any
claim by a third party relating directly or indirectly to Licensee's labeling of
the Inventory.

7. TERM

     This Agreement shall commence and be effective upon the Closing Date and
shall remain in full force and effect for the term set forth in Section 2.3,
unless earlier terminated as follows:

     (a) by mutual written consent of the Parties at any time;

     (b) upon written notice by Licensor if Licensee is in material breach of
     this Agreement, including exceeding the scope of the Inventory Trademark
     License or failing to comply with the provisions of Article 4, and Licensee
     fails to correct said breach to Licensor's reasonable satisfaction within
     fifteen (15) days after receipt of written notice of such breach from
     Licensor;

     (c) upon written notice by Licensor if Licensee commits any breach other
     than a material breach, and Licensee fails to correct said breach to
     Licensor's reasonable satisfaction within thirty (30) days after receipt of
     written notice of such breach from Licensor; or

                                       -4-

<PAGE>

     (d) automatically in the event that Licensee is adjudged bankrupt or
     insolvent, or shall generally not pay its debts as they become due, or
     makes an assignment for the benefit or creditors, or an arrangement
     pursuant to any bankruptcy law, or if the Licensee discontinues its
     business related to the Products, or if a receiver is appointed for the
     Licensee or for the Licensee's business.

8. TERMINATION

     Immediately upon, and at all times after, termination of this Agreement:

     (a) Sections 3.1, Section 3.2, Sections 3.3, and Sections 7 through 16 in
     their entirety shall survive termination of this Agreement.

     (b) All rights granted to the Licensee shall revert to the Licensor.

     (c) Licensee shall claim no rights to the Licensed Marks, either directly
     or indirectly, in connection with the manufacture, sale, promotion or
     distribution of Licensee's products or any other part of Licensee's
     business.

9. NOTICES

     All communications, notices and consents provided for herein shall be in
writing and be given in person or by means of telex, facsimile or other means of
wire transmission (with request for assurance of receipt in a manner typical
with respect to communications of that type), by overnight courier or by mail,
and shall become effective: (a) on delivery if given in person; (b) on the date
of transmission if sent by telex, facsimile or other means of wire transmission;
(c) one (1) business day after delivery to the overnight service; or (d) four
(4) business days after being deposited in the United States mails, with proper
postage and documentation, for first-class registered or certified mail,
prepaid.

     Notices shall be addressed as follows:

          If to Licensee, to:

               ImaRx Therapeutics,  Inc.
               1635 East 18th Street
               Tucson, Arizona 85719
               Attn: Greg Cobb
               Facsimile Number: (520) 791-2437

          with copies to:

               DLA Piper Rudnick Gray Cary LLP
               701 Fifth Avenue, Ste 700
               Seattle, Washington 98104
               Attn: Jeff Harmes

                                       -5-

<PAGE>

               Facsimile Number: (206) 839-4801

          If to Licensor, to:

               Abbott Laboratories
               100 Abbott Park Road
               Building AP6D, Department 364
               Abbott Park, Illinois 60064-6020
               Attn: General Counsel
               Facsimile Number: (847) 938-6277

provided, however, that if any party shall have designated a different address
by notice to the others, then to the last address so designated.

10. RELATIONSHIP OF THE PARTIES

     This Agreement does not create an employment agreement, agency,
partnership, franchise or joint venture relationship between the Parties, and
the Licensee shall have no power to obligate or bind the Licensor in any manner
whatsoever.

11. APPLICABLE LAW

     This Agreement shall be construed and enforced in accordance with and
governed by the laws of the State of Delaware without regard to the conflicts of
laws provisions of any jurisdiction.

12. NO ASSIGNMENT

     (a) The rights, duties, benefits and obligations of each Party hereto shall
     inure to the benefit of and be binding upon any successors, assigns or
     delegates permitted under this Section 12.

     (b) Licensee shall not assign or otherwise transfer (whether by change of
     control, merger, consolidation, operation of law or otherwise) this
     Agreement, or sublicense or delegate any of its rights or benefits, duties
     or obligations hereunder without Licensor's prior written consent. Any
     attempted assignment or other transfer or delegation without Licensor's
     prior written consent shall be null, void and without effect. The
     restrictions in this Section 12(b) shall not apply to any transfer or
     assignment of Licensee's rights and obligations under the Asset Purchase
     Agreement which are permitted under the terms of that agreement.

13. CAPTIONS

                                       -6-

<PAGE>

     The captions used in connection with the paragraphs and sub-paragraphs of
this Agreement are inserted only for purpose of reference. Such captions shall
not be deemed to govern, limit, modify or in any other manner affect the scope,
meaning or intent of the provisions of this Agreement or any part thereof, nor
shall such captions otherwise be given any legal effect.

14. CONSTRUCTION

     The language in all parts of this Agreement shall be construed, in all
cases, according to its fair meaning. The Parties acknowledge that each Party
and its counsel have reviewed and revised this Agreement and that any rule of
construction to the effect that any ambiguities are to be resolved against the
drafting Party shall not be employed in the interpretation of this Agreement.
Words in the singular shall be deemed to include the plural and vice versa and
words of one gender shall be deemed to include the other gender as the context
requires. The terms "hereof," "herein," and "herewith" and words of similar
import shall, unless otherwise stated, be construed to refer to this Agreement
as a whole and not to any particular provision of this Agreement. Article,
Section and Schedule references are to the Articles, Sections and Schedules to
this Agreement unless otherwise specified. Unless otherwise stated, all
references to any agreement shall be deemed to include the exhibits, schedules
and annexes to such agreement. The word "including" and words of similar import
when used in this Agreement shall mean "including, without limitation," unless
the context otherwise requires or unless otherwise specified. The word "or"
shall not be exclusive. Unless otherwise specified in a particular case, the
word "days" refers to calendar days. References herein to this Agreement or any
other agreement shall be deemed to refer to this Agreement or such other
agreement as of the date of such agreement and as it may be amended thereafter,
unless otherwise specified.

15. ENTIRE AGREEMENT; NO WAIVER

     This Agreement and the provisions of any other agreement specifically
referenced herein constitute the entire understanding between the parties
concerning the subject matter hereof and supersede all written or oral prior
agreements or understandings with respect thereto. No waiver or modification of
any terms of this Agreement shall be valid unless in writing and signed by an
authorized representative of both parties. The failure of either Party to
enforce any condition or part of this Agreement at any time shall not be
construed as a waiver of that condition or part, nor shall it forfeit any rights
to future enforcement thereof.

16. SEVERABILITY

     In the event that any provision of this Agreement is judicially determined
to be void or unenforceable, such provision shall be construed to be separable
from the other provisions of this Agreement which shall retain full force and
effect.

17. CONSIDERATION

                                       -7-

<PAGE>

     The parties' mutual obligations under this Agreement and their agreement to
enter into the Asset Purchase Agreement constitute good and valuable
consideration, the sufficiency of which is hereby acknowledged.

                                       -8-

<PAGE>

     IN WITNESS WHEREOF, each of the Parties hereto has caused this Agreement to
be executed on its behalf by its duly authorized officer, all as of the date
first set forth above.

IMARX THERAPEUTICS, INC.:                ABBOTT LABORATORIES:

BY: /s/ Evan C. Unger                   BY: /s/ Sean E. Murphy
    --------------------------------        --------------------------------
    Evan C. Unger                           Sean E. Murphy
TITLE: President and CEO                TITLE: Vice President, Global Licensing/
                                               New Business Development
DATE: April 18, 2006                    DATE: April 17, 2006
      -----------------------                 -----------------------

<PAGE>

                                   SCHEDULE 1

ABBOKINASE
<PAGE>

                     SCHEDULE 2.1(H) - PRODUCT APPLICATIONS

1.   New Drug Application 76-1021.

2.   The following supplements to NDA 76-1021 have been approved or are pending
     approval by the Food and Drug Administration (the "FDA").

<TABLE>
<CAPTION>
                 Date
 Supplement   Supplement     Type of                                               Date Supplement
  Number       Submitted   Supplement            Supplement Description                Approved
-----------   ----------   ----------   ----------------------------------------   ---------------
<S>           <C>          <C>          <C>                                        <C>
   S-076      12/31/01       PAS        Provides for; (i) changes in the               10/10/02
                                        procurement and processing of
                                        neonatal kidney cells; (ii)
                                        improvements in the manufacture and
                                        testing of the drug substance and
                                        drug product; (iii) revised
                                        release specifications for the
                                        drug substance and drug product;
                                        (iv) a revised lot release
                                        protocol; (v) withdrawal of the
                                        OPEN-CATH(R) dosage strengths; and
                                        (vi) revised labeling. Labeling
                                        revisions include updated
                                        information regarding product
                                        source and adverse reactions, as
                                        well as withdrawal of the coronary
                                        artery thrombosis and catheter clearance
                                        indications.

   S-083       05/02/03      CBE-30     Provides for the addition of a                 09/25/03
                                        0.45 um pre-filter and a 0.22 um
                                        filtration step immediately prior
                                        to the ultrafiltration step in the
                                        urokinase isolation process.

   S-089       09/30/03      CBE-30     Provides for the storage of the                04/01/04
                                        CG-50 resin at an alkaline pH as an
                                        alternative regeneration process to
                                        manage bioburden control.

   S-090       11/01/03      CBE-0      Provides for the replacement of                05/03/04
                                        the drug substance relative
                                        amidolytic potency specification with an
                                        amidolytic potency specification;
                                        and to revise the drug product
                                        endotoxin test method.
</TABLE>

<PAGE>

<TABLE>
<S>           <C>          <C>          <C>                                        <C>
    S-092       1/6/04       CBE-0      Provides for the revision of the               7/8/04
                                        lot release protocol to include
                                        changes to the drug substance
                                        specifications and drug
                                        product bacterial endotoxin test method.

    S-095      4/26/04       PAS        Provides for the storage of drug               Pending
                                        substance at <-50 degrees C in a Nalgene
                                        plastic bottle.

    TBD        5/19/04       CBE-30     Provides for a test location                   Pending
                                        change for the drug substance in vitro
                                        adventitious virus test from a contract
                                        lab to Abbott Labs.
</TABLE>

<PAGE>

                        SCHEDULE 2.1(J) - STOCK-IN-TRADE

Abbokinase Lot# 15-342-S2 For Clinical Study M03-585

180 vials in Abbott's Clinical Warehouse
120 vials with Clinical Study Cooperators

<PAGE>

                         SCHEDULE 2.1(K) - RAW MATERIALS

<TABLE>
<CAPTION>
Abbott
Code                    Unit of
Number       Qty.       Measure     Code Description      Retest
------   ------------   -------   ---------------------   ------
<S>      <C>            <C>       <C>                     <C>
72706            1.85     Ltr     TRYPSIN                 2 Year
59384       12,582.00     Ltr     Protein Hydrolysate     2 Year
11379      100,000.00     gm      Aminocaproic Acid           NA
19670    1,518,419.50     gm      Dextrose                2 Year
13156           52.99     lt      Octyl Alcohol           2 Year
13937        2,042.57     kg      Ion Exchange Resin      2 Year
16131    1,179,540.00     ml      BEE                     1 Year
21442        1,139.00     lt      Bovine Serum            1 Year
22441    2,757,240.00     ug      EGF, Growth Factor      3 Year
23366      117,420.88     gm      Dextran, Cross Linked   2 Year
23373       95,128.60     gm      Dextran, Cross Linked   2 Year
24092        6,115.00     ml      DMSO                    2 Year
33802       30,268.00     gm      L-Glutamine             2 Year
43740      327,231.00     gm      Magnesium Sulfate       2 Year
44488    3,565,915.00     gm      MED-199                 2 Year
56664        5,944.20     gm      Phenol Red              2 Year
66340    1,570,960.00     gm      Sodium Phosphate        2 Year
72704          856.20     gm      Trypsin Powder          2 Year
74813      200,992.60     gm      Vitamin BME             2 Year
87324       13,575.00     lt      Serum, Newborn Calf     1 Year
</TABLE>

<PAGE>

                       SCHEDULE 2.5 - MIXED GPO CONTRACTS

1.   Agreement for Pharmaceutical Products by and between Abbott Laboratories
     Inc. and Broadlane, Inc., dated as of August 21, 2001. *

2.   Abbokinase(R) (urokinase) Contract between Good Samaritan Hospital and
     Abbott Laboratories Inc. dated as of June 25, 2003.

3.   Abbokinase(R) (urokinase) Contract between Kenosha Hospital and Medical
     Center and Abbott Laboratories Inc. dated as of Aug. 1, 2003.

4.   Abbokinase(R) (urokinase} Contract between Littleton Adventist Hospital
     and Abbott Laboratories Inc. dated as of Sept. 1, 2003.

5.   Abbokinase(R) (urokinase) Contract between Penrose St. Francis Health
     Center and Abbott Laboratories Inc. dated as of August 1, 2003.

6.   Abbokinase(R) (urokinase) Contract between Porter Adventist Hospital and
     Abbott Laboratories Inc. dated as of Sept. 1, 2003.

7.   Abbokinase(R) (urokinase) Contract between St. Anthony Central Hospital
     and Abbott Laboratories Inc. dated as of Oct. 1, 2003.

8.   Abbokinase(R) (urokinase) Contract between St. Catherine's Hospital and
     Abbott Laboratories Inc. dated as of Aug. 1, 2003.

9.   Abbokinase(R) (urokinase) Contract between St. John's Health System and
     Abbott Laboratories Inc. dated as of Oct. 22, 2002.

10.  Abbokinase(R) (urokinase) Contract between St. John's Hospital and Abbott
     Laboratories Inc. dated as of March 1, 2003.

11.  Abbokinase(R) (urokinase) Contract between St. Joseph's Medical Center and
     Abbott Laboratories Inc. dated as of Oct. 15, 2003.

12.  Abbokinase(R) (urokinase) Contract between St. Mary's Medical Center and
     Abbott Laboratories Inc. dated as of July 1, 2003.

13.  Abbokinase(R) {urokinase) Contract between St. Vincent Infirmary and Abbott
     Laboratories Inc. dated as of May 29, 2003.

14.  Vendor Agreement between Abbott Laboratories Inc. and MedAssets HSCA, Inc.,
     dated as of September 3, 2002, as amended.

15.  Contract between University of Michigan Health System and Abbott
     Laboratories Inc. dated as of Oct. 1, 2004.

16.  Contract between Abbott Laboratories Inc., Pharmaceutical Products
     Division, and the State of Minnesota, Commissioner of Administration (on
     behalf of the

<PAGE>

     Minnesota Multistate Contracting Alliance for Pharmacy), dated as of June
     2, 2004.

17.  Pharmacy Supplier Agreement between Abbott Laboratories Inc. and Novation,
     LLC, dated as of March 13, 2001, as amended. *

18.  Pharmaceutical Purchasing Agreement (PACT) between Abbott Laboratories Inc.
     and Purchasing Alliance for Clinical Therapeutics, dated as of April 1,
     2004. *

19.  Group Purchasing Agreement between Abbott Laboratories Inc. and Premier
     Purchasing Partners, L.P., dated as of July 1, 1998, as amended. *

20.  Corporate Strategic Agreement between Abbott Laboratories Inc. and Johns
     Hopkins Health System Corporation, dated as of June 1, 2002.

21.  Abbokinase(R) (urokinase) Contract between HC Pharmacy and Abbott
     Laboratories Inc. dated as of May 1, 2003.

22.  Network Agreement between Abbott Laboratories and Kaiser Permanente Medical
     Care Program, dated March 16, 2006 and effective April 1, 2006. *

*    INDICATES A "TOP FIVE" MIXED GPO CONTRACT FOR PURPOSES OF SECTION 2.5

<PAGE>

                              SCHEDULE 5.4 - TITLE

None.

<PAGE>

                       SCHEDULE 5.5 - INTELLECTUAL PROPERTY

None.

<PAGE>

                            SCHEDULE 5.6 - LITIGATION

None.

<PAGE>

                         SCHEDULE 5.7 - SELLER CONSENTS

1.   Abbokinase Fill and Finish Agreement between Hospira, Inc. and Abbott
     Laboratories, dated April 16, 2004.

2.   Notification to the FDA of the transfer of NDA 76-1021 will be required.

<PAGE>

                          SCHEDULE 5.9 - FINANCIAL DATA

                              ABBOKINASE SALES DATA

<TABLE>
<CAPTION>
                                          Wholesaler
                       IMS Data(a)        Reports To
                  ---------------------    Abbott(b)
                    Dollars      Units       Units
                  -----------   -------   ----------
<S>               <C>           <C>       <C>
Qtr 1, 2005       $ 6,422,215    17,058     15,579
Qtr 2, 2005       $ 5,066,668    13,426     11,555
Qtr 3, 2005       $ 3,871,022    10,323     10,742
Qtr 4, 2005       $ 3,745,832     9,808     10,275
                  -----------   -------     ------
Total Year 2005   $19,105,737    50,615     48,151
                  ===========   =======     ======

Monthly Data
October, 2005     $ 1,162,662     3,044      3,166
November, 2005    $ 1,181,214     3,087      3,329
December, 2005    $ 1,401,956     3,677      3,780
January, 2006     $ 1,224,207     2,992      3,414
February, 2006    $ 1,097,515     2,718      3,577
</TABLE>

(a)  Source: IMS Dataview

(b)  Reflects sales units reported by the top 3 wholesalers (Cardinal, McKesson,
     and ABC).

<PAGE>

                   SCHEDULE 5.12 - GOVERNMENTAL AUTHORIZATIONS

None.

<PAGE>

                          SCHEDULE 6.3 - BUYER CONSENTS

1.   Approval of the board of directors of ImaRx Therapeutics, Inc.

2.   Notification to the FDA of the transfer of NDA 76-1021 will be required.

<PAGE>

                           SCHEDULE 6.8 - INDEBTEDNESS

1.   Claim for patent reimbursement by Bracco Diagnostics, Inc. against ImaRx
     Therapeutics, Inc. in the amount of $218,856.

2.   Secured Promissory Note made by ImaRx Therapeutics, Inc. in favor of Abbott
     Laboratories, dated as of September 30, 2005 in the initial principal
     amount of $15,000,000, plus accrued interest thereon.<PAGE>

                                                                   Exhibit 10.13

                               SECURITY AGREEMENT

     This Security Agreement (this "AGREEMENT") is made as of April 14, 2006, by
ImaRx Therapeutics, Inc., a Delaware corporation (the "COMPANY"), in favor of
Abbott Laboratories, an Illinois corporation ("HOLDER").

                                     RECITAL

     Holder and the Company have executed a Secured Promissory Note (a "NOTE")
in connection with the closing of the transactions set forth in that certain
Asset Purchase Agreement dated as of April 10, 2006, between the Company and
Holder (the "ASSET PURCHASE AGREEMENT"). Pursuant to the terms of the Asset
Purchase Agreement, the Company is required to execute and deliver this
Agreement for the purpose of granting Holder a security interest in certain of
the Company's assets.

                                    AGREEMENT

     NOW, THEREFORE, in consideration of the representations, warranties and
covenants herein contained and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto
hereby agree as follows.

     1. Capitalized Terms. Capitalized terms not defined herein shall have the
meanings given such terms in the Note.

     2. Grant of Security Interest. To secure the complete and timely
satisfaction of all Obligations, the Company hereby grants to Holder a
continuing, first priority security interest (with power of sale, to the extent
permitted by law or such other security interests as may exist as of the date of
this Agreement, upon occurrence of an Event of Default), in all of the Company's
right, title and interest in and to all of the collateral set forth on attached
Exhibit A (the "COLLATERAL"). The Company represents that Holder will have a
continuing, first priority security interest in the Collateral, subject to
Holder's commercially reasonable steps to protect its interest. The parties
further agree that the Company may not sell any Collateral (other than sales of
the Inventory in the ordinary course of the Company's business) until the
Obligations are paid in full.

     3. Perfection of Security Interests. At any time and from time to time, the
Company will execute, file, and record any notice, financing statement, or other
instrument, reasonably necessary to create, continue, or perfect the security
interest granted by this Agreement or to enable Holder to exercise or enforce
its rights under this Agreement.

     4. Term. The term of this Agreement will extend until all Obligations under
the Note have been indefeasibly paid in full, as reasonably determined by the
parties, at which time the Company and any of its duly appointed officers is
hereby authorized to file any termination statement under the Uniform Commercial
Code in effect in any jurisdiction to terminate the financing statements that
evidence the security interest in the Collateral created by this Agreement and
the Note.

<PAGE>

     5. Rights and Remedies Upon Default. Beginning on the date on which any
Event of Default shall have occurred, and while such Event of Default is
continuing:

          (a) Holder may exercise, in addition to all other rights and remedies
granted to it under this Agreement, all rights and remedies of a secured party
under the Uniform Commercial Code.

          (b) The Company hereby waives presentment, demand, protest or any
notice (to the maximum extent permitted by applicable law) of any kind in
connection with this Agreement or any Collateral.

          (c) The Company shall, at the request of Holder, assemble the
Collateral at such place or places as may be reasonably designated by Holder.

          (d) Holder may, in its sole discretion, in its name or in the name of
the Company or otherwise, demand, sue for, collect or receive any money or
property at any time payable or receivable on account of or in exchange for any
of the Collateral, but shall be under no obligation to do so.

          (e) Holder may, upon ten (10) days' prior written notice to the
Company of the time and place (which notice the Company hereby agrees is
commercially reasonable notification for purposes hereof), with respect to the
Collateral or any part thereof which shall then be or shall thereafter come into
the possession, custody or control of Holder, sell, lease, assign or otherwise
dispose of all or any part of such Collateral, at such place or places as Holder
deems best, and for cash or for credit or for future delivery (without thereby
assuming any credit risk), at public or private sale, without demand of
performance or notice of intention to effect any such disposition or of the time
or place thereof (except such notice as is required above or by applicable
statute and cannot be waived), and Holder or anyone else may be the purchaser,
lessee, assignee or recipient of any or all of the Collateral so disposed of at
any public sale (or, to the extent permitted by law, at any private sale) and
thereafter hold the same absolutely, free from any claim or right of whatsoever
kind, including any right or equity of redemption (statutory or otherwise), of
the Company, any such demand, notice and right or equity being hereby expressly
waived and released. Holder may, without notice or publication, adjourn any
public or private sale or cause the same to be adjourned from time to time by
announcement at the time and place fixed for the sale, and such sale may be made
at any time or place to which the sale may be so adjourned.

     6. Release of Security Interest. Upon the indefeasible payment in full of
the Obligations, Holder will execute and deliver to the Company all deeds,
assignments and other instruments, and will take such other actions, as may be
necessary or proper to re-vest in the Company full title to the Collateral,
subject to any disposition which may have been made by Holder pursuant to this
Agreement.

     7. Certain Restrictions. The Company agrees that until the Obligations have
been indefeasibly paid in full, the Company will not sell or assign its interest
in, or grant any license under, other than in the ordinary course of business in
consultation with Holder, the Collateral, or enter into any other agreement with
respect to the Collateral that is inconsistent with the

                                        2

<PAGE>

Company's obligations under this Agreement, without the prior written consent of
Holder; provided, however, that the Company may assign the Collateral to an
Affiliate if the Company fully guarantees such Affiliate's performance of all of
the Company's obligations hereunder. The Company further agrees that it will not
take any action, or permit any action to be taken by others subject to its
control, including licensees, or fail to take any action (solely with respect to
any Collateral that are registered patents or registered trademarks), which
would affect the validity or enforcement of the rights transferred to Holder
under this Agreement. Further, the Company covenants and agrees that, until the
Obligations hereunder have been indefeasibly paid in full, the Company will
preserve and maintain the Collateral in good working condition and will protect
the Collateral against spoilage, deterioration and any other wasting.

     8. Expenses. All expenses incurred in connection with the performance by
the Company and Holder of any of the agreements set forth in this Agreement will
be borne by the Company. All fees, costs and expenses, of whatever kind or
nature, including reasonable attorneys' and paralegals' fees and legal expenses,
incurred by Holder in connection with the filing or recording of any documents
(including all taxes in connection therewith) in public offices, the payment or
discharge of any taxes, counsel fees, maintenance fees, encumbrances or
otherwise in protecting, maintaining or preserving the Collateral will be borne
by and paid by the Company.

     9. Severability. The provisions of this Agreement are severable, and if any
clause or provision is held invalid and unenforceable in whole or in part in any
jurisdiction, then such invalidity or unenforceability will affect only such
clause or provision, or part of such clause or provision, in such jurisdiction,
and will not in any manner affect such clause or provision in any other
jurisdiction, or any other clause or provision of this Agreement in any
jurisdiction.

     10. Modification. This Agreement cannot be altered, amended or modified in
any way, except as specifically provided in writing and signed by the Company
and Holder.

     11. Binding Effect; Benefits. This Agreement will be binding upon the
Company and its successors and permitted assigns, and will inure to the benefit
of Holder, its successors, nominees and assigns.

     12. Governing Law. This Agreement shall be governed in all respects by the
internal laws of the State of Delaware, excluding that body of law relating to
conflict of laws and choice of law.

     13. Headings. Paragraph headings used in this Agreement are for convenience
only and will not modify the provisions that they precede.

                            [Signature pages follow.]

                                        3

<PAGE>

     IN WITNESS WHEREOF, the undersigned has caused this Security Agreement to
be duly executed by its officer thereunto duly authorized as of the first date
written above.

                                        COMPANY:
                                        IMARX THERAPEUTICS, INC.

                                        By: /s/ Evan C. Unger
                                            ------------------------------------
                                        Name: Evan C. Unger
                                        Title: President and Chief Executive
                                               Officer

                                        HOLDER:
                                        ABBOTT LABORATORIES

                                        By: /s/ Sean E. Murphy
                                            ------------------------------------
                                        Name: Sean E. Murphy
                                        Its: Vice President, Global
                                             Licensing/New Business Development

<PAGE>

                                    EXHIBIT A

                                   COLLATERAL

     The Collateral consists of (i) the Purchased Assets (as defined in the
Asset Purchase Agreement) transferred to the Company by Abbott Laboratories, an
Illinois corporation ("ABBOTT"), pursuant to that certain Asset Purchase
Agreement (the "ASSET PURCHASE AGREEMENT") dated as of April 10, 2006, between
the Company and Abbott, (ii) any written data or research related to the
Purchased Assets or developments and improvements in the intellectual property
included in the Purchased Assets created by the Company subsequent to the
closing of the sale of such Purchased Assets to the Company, (iii) any and all
proceeds from the sale or transfer of the Purchased Assets other than Inventory,
(iv) those proceeds from the sale or transfer of the Inventory that are to be
held in escrow, pursuant to the terms of that certain Escrow Agreement, by and
between the Company and Abbott, dated as of April 14, 2006 (the "Escrow
Agreement") (together with romanette (iii), the "PROCEEDS") and (v) any other
funds deposited by ImaRx into the escrow account governed by the Escrow
Agreement pursuant to Section 1.1(a) thereof.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]